PMEF
MLYS icon

Point72 Middle East FZE’s Mineralys Therapeutics MLYS Stock Holding History

Point72 Middle East FZE’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-135
Closed -$1.16K – 833
2023
Q4 		$1.16K Buy
+135
New +$1.06K ﹤0.01% 1440
2023
Q2 		– Sell
-36,822
Closed -$577K – 1879
2023
Q1 		$577K Buy
+36,822
New +$620K 0.02% 663

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Point72 Middle East FZE's MLYS Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Mineralys Therapeutics (MLYS) in Q1 2024, closing a stake of 135 shares — an estimated $1.16K sold.

Point72 Middle East FZE first reported a position in MLYS in Q1 2023 and held it in 2 quarters. The position peaked at $577K in Q1 2023. 92 funds tracked by Wall St. Rank hold MLYS as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Mineralys Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 135 Mineralys Therapeutics shares in Q1 2024, an estimated $1.16K.
  • Point72 Middle East FZE first reported a position in Mineralys Therapeutics in Q1 2023 and held it in 2 quarters.
  • Point72 Middle East FZE's Mineralys Therapeutics position peaked at $577K in Q1 2023.
  • 92 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.